<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David R Holmes, Jr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Sorajja, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Donald Cutlip, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Saltzman, MD, FACP, FACG, FASGE, AGAF</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H5971548"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Periprocedural and long-term antithrombotic (anticoagulant or antiplatelet) therapy is an integral part of percutaneous coronary intervention (with either coronary artery stenting or percutaneous transluminal coronary angioplasty). Antithrombotic therapy has been shown to prevent periprocedural and long-term cardiovascular events such as stent thrombosis and recurrent myocardial infarction. (See  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a> and  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use"</a>.)</p><p>Current antithrombotic regimens have the potential to result in either new gastrointestinal (GI) bleeding or to exacerbate chronic episodic GI bleeding. For those with GI bleeding, there is significant attributable morbidity and mortality. However, in many such patients, alternatives to percutaneous coronary intervention (PCI) may be limited. Given the fact that over one million PCI procedures are performed annually, and that antithrombotic therapy has become more aggressive, there is a need to understand the unique challenges in the prevention and management of GI bleeding in this patient population.</p><p>Furthermore, with the increasing adoption of a radial as compared to femoral artery approach, GI bleeding may be the most common type of bleeding associated with PCI.</p><p>This topic focuses on periprocedural and long-term GI bleeding in patients undergoing PCI. Issues of GI bleeding in patients on chronic anticoagulant or nonsteroidal antiinflammatory therapy are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"</a>.)</p><p>Periprocedural bleeding not related to the GI tract in patients undergoing PCI is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1573.html" rel="external">"Periprocedural bleeding in patients undergoing percutaneous coronary intervention"</a>.)</p><p class="headingAnchor" id="H5971556"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>While strict definitions of peri-procedural bleeding in percutaneous coronary intervention (PCI) patients have been adopted, there is less consensus on what constitutes clinically significant gastrointestinal (GI) bleeding. (See  <a class="medical medical_review" href="/z/d/html/1573.html" rel="external">"Periprocedural bleeding in patients undergoing percutaneous coronary intervention"</a>.)</p><p>Common types of GI bleeding in PCI patients are the occurrence of hematemesis, melena, or red blood per rectum, and endoscopic evidence of the source of GI bleeding. Significant reduction in hemoglobin (≥2 g/dL) or need for transfusion has also been required in some, but not all, studies [<a href="#rid1">1-5</a>].</p><p class="headingAnchor" id="H5971563"><span class="h1">INCIDENCE AND RISK FACTORS</span><span class="headingEndMark"> — </span>The combined use of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and a platelet P2Y<sub>12</sub> receptor blocker, which is common after percutaneous coronary intervention (PCI) with stenting, is associated with an increased risk of gastrointestinal (GI) bleeding (overall incidence of 0.7 to 2.4 percent at 30 days), which accounts for approximately 15 percent of all periprocedural bleeding events [<a href="#rid1">1-3,5,6</a>]. This increase in early GI bleeding has also been associated with the intensity of antithrombotic therapy, advanced age, primary PCI for ST-elevation myocardial infarction, shock or inotrope requirement, cardiac arrest, baseline anemia, smoking, diabetes, duration of antithrombotic study drug administration, female sex, prior stroke, chronic kidney disease, history of prior bleeding or complicated peptic ulcer disease, and heart failure [<a href="#rid2">2,3,6</a>]. Triple antithrombotic therapy (dual antiplatelet therapy plus an oral anticoagulant) significantly increased the risk of GI bleeding (15.6 percent in patients on triple therapy versus 6.7 in patients not on triple therapy) [<a href="#rid7">7</a>].</p><p>The risk factors for GI bleeding in patients on long-term therapy with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> are a history of complicated peptic ulcer disease, bleeding (15 percent recurrence of GI bleeding at one year on 100 mg aspirin per day for example), or at least two of the following: age &gt;65 years (1 percent per year increase per decade), concurrent use of a second nonsteroidal antiinflammatory drug (two- to fourfold increase in risk), glucocorticoid therapy, or anticoagulant, high-dose aspirin or nonsteroidal antiinflammatory drug, a history of an uncomplicated ulcer, or Helicobacter pylori (H. pylori) infection (fivefold increase in risk) [<a href="#rid8">8-12</a>]. This issue is discussed in detail separately.</p><p class="headingAnchor" id="H10194391"><span class="h2">Aspirin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a><strong> </strong>(and other<strong> </strong>nonsteroidal antiinflammatory drugs) cause gastrointestinal bleeding due to their irritation of the gastroduodenal mucosa. However, for patients undergoing PCI with stenting, withholding aspirin is an option only in rare cases. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use"</a> and  <a class="medical medical_review" href="/z/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"</a>.)</p><p class="headingAnchor" id="H5971578"><span class="h2">Platelet P2Y12 receptor blockers</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> and other platelet P2Y<sub>12</sub> receptor blockers inhibit platelet activation by binding the platelet adenosine diphosphate (ADP) receptor, leading to inhibition of ADP-dependent activation of the glycoprotein IIb-IIIa complex. While the use of these drugs is associated with an increase in the risk of GI bleeding, the magnitude of the increase has not been well studied. In a large cohort study from Denmark that included over 75,000 patients who took clopidogrel, the long-term risk of GI events (bleeding, ulcer, or gastritis) increased from about 2 to about 6 percent, comparing never-users with users [<a href="#rid13">13</a>]. Among individuals taking no antiplatelet therapy, the crude risk of GI events was 1.6 percent; among non-clopidogrel <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> users, the risk was 4.1 percent; among clopidogrel non-aspirin users, the risk was 6.1 percent; and among patients on both agents the risk was 6.6 percent.</p><p>Platelet P2Y<sub>12</sub> receptor blockers are not believed to be directly ulcerogenic. In a Scandinavian study of healthy volunteers with upper endoscopy, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> (75 mg per day), unlike <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (325 mg per day), was not associated with macroscopic changes in gastroduodenal mucosa after eight days of therapy [<a href="#rid14">14</a>]. Thus, some have advocated P2Y<sub>12</sub> receptor blocker monotherapy for patients with gastrointestinal intolerance to aspirin. However, clopidogrel and other adenosine diphosphate-receptor antagonists can impair ulcer healing, and have been associated with increased hemorrhagic risk in patients with a prior history of GI bleeding [<a href="#rid15">15,16</a>]. Platelet aggregation leads to the release of platelet-derived growth factors (eg, vascular endothelial growth factor or VEGF) that promote angiogenesis and endothelial cell proliferation required for ulcer healing [<a href="#rid17">17</a>].</p><p>The incidence of GI bleeding with the more potent drugs <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> and <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> has not been well studied. There is some evidence suggesting that the risk is greater than with <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid18">18</a>].</p><p><a class="drug drug_general" data-topicid="102219" href="/z/d/drug information/102219.html" rel="external">Cangrelor</a>, an intravenous rapid onset/offset P2Y12 inhibitor that has been approved, is associated with increases in the rates of minor but not moderate or severe bleeding in comparison to <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> in patients undergoing PCI [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H5971585"><span class="h2">Dual antiplatelet therapy</span><span class="headingEndMark"> — </span>The incidence, predictors, and outcomes of GI bleeding were evaluated in an observational study of 1852 patients who underwent PCI with drug-eluting stent placement and were taking <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid20">20</a>]. The rate of hospitalized GI bleeding was 2.7 percent; a history of GI bleeding was the most important independent predictor of future GI bleeding (odds ratio 5.0). The 30-day mortality after GI bleeding was 3.7 compared to 0 percent in a group of comparable individuals who had not bled.</p><p>Little or no data exist on periprocedural incidence of GI bleeding, possibly due to the subacute time course required for pathogenesis in most patients.</p><p class="headingAnchor" id="H5971608"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Gastrointestinal (GI) bleeding is associated with increased early and late mortality, as well as ischemic outcomes and a higher incidence of stent thrombosis. The reasons for poorer outcome in patients with GI bleeding are not clear, but bleeding may be either directly causative or be a marker for morbidity and heightened patient risk. (See  <a class="medical medical_review" href="/z/d/html/1582.html" rel="external">"Coronary artery stent thrombosis: Incidence and risk factors"</a> and  <a class="medical medical_review" href="/z/d/html/1573.html" rel="external">"Periprocedural bleeding in patients undergoing percutaneous coronary intervention", section on 'Outcomes after bleeding'</a>.)</p><p>The following are examples of this association:</p><p class="bulletIndent1"><span class="glyph">●</span>A comprehensive evaluation of the prognostic impact of GI bleeding was performed in the ACUITY trial of 13,819 acute coronary syndrome (ACS) patients (7789 patients with percutaneous coronary intervention [PCI]) [<a href="#rid3">3</a>]. GI bleeding occurred in 1.3 percent and was a significant independent predictor of outcomes at 30 days with hazard ratios of 4.87 for mortality, 1.74 for nonfatal myocardial infarction, and 1.94 for composite ischemia. The increased risk of each of the end points persisted at one-year follow-up Moreover, the stent thrombosis rate was significantly higher than in those with, as compared to those without, GI bleeding (5.8 versus 2.4 percent) [<a href="#rid3">3</a>]. In a study examining patients enrolled in the Primary Angioplasty in Myocardial Infarction (PAMI) trials, GI bleeding was associated with a significantly longer hospital stay (12.6 ±13 versus 6.4 ±5.3 days) and a higher incidence of death both in-hospital (10 versus 2.8 percent) and at six-month follow-up (14 versus 4.6) [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a retrospective study of over 20,000 PCI patients, the 30-day mortality was significantly increased in those with GI bleeding compared to those without (20.5 versus 2.4 percent) [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The CHARISMA trial enrolled patients with either established atherosclerosis or multiple risk factors, and randomized patients to either <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> 75 mg/day or placebo, in addition to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 75 mg to 162 mg/day. GI bleeding was more common in the clopidogrel-treated patients, occurred most frequently in the first year of the study, and was independently and significantly associated with all-cause mortality (1.82, 95% CI 1.24-2.69) [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 6212 patients in the Bern PCI registry, GI bleeding was associated with increased all-cause mortality (adjusted hazard ratio 3.40, 95% CI 1.67-6.92) [<a href="#rid7">7</a>].</p><p></p><p class="headingAnchor" id="H5971615"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Gastrointestinal (GI) bleeding in a patient who has recently undergone percutaneous coronary intervention (PCI) poses unique therapeutic challenges. The need to attain hemostasis often requires the premature discontinuation of antithrombotic therapies, which leads to an increased risk of recurrent myocardial ischemic events, including stent thrombosis [<a href="#rid22">22,23</a>]. (See  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a> and  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Duration and Type of Antiplatelet Treatment'</a>.)</p><p>In addition, acute bleeding itself leads to platelet activation and initiation of the clotting cascade for hemostasis, potentially increasing the risk of thrombosis in the absence of antiplatelet therapy.</p><p>In the event of acute GI bleeding, the decision to discontinue <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, P2Y<sub>12</sub> receptor blockers, or other antithrombotic therapy is made on an individual patient basis, balancing the likelihood and consequences for either a thrombotic or a hemorrhagic event action [<a href="#rid24">24</a>]. The following should be kept in mind when deciding further management:</p><p class="bulletIndent1"><span class="glyph">●</span>Some (but not all) randomized trials have demonstrated increased risk of ischemic events in PCI patients receiving <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> monotherapy in comparison with dual antiplatelet therapy (aspirin and P2Y<sub>12</sub> receptor blocker) [<a href="#rid25">25-29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Efforts should be made to continue antiplatelet therapy unless the bleeding is life threatening, particularly if coronary stenting has been recently performed. For patients who have undergone PCI with drug-eluting stents who experience GI bleeding, it is reasonable to change from dual antiplatelet therapy to monotherapy at three months for stable ischemic heart disease and at six months for acute coronary syndromes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with clinically suspected GI bleeding, a gastroenterology evaluation should be pursued in a timely fashion in accordance with the urgency of the clinical presentation, with appropriate endoscopy performed for both confirmation of the diagnosis and deliverance of therapy. It is important to note that bleeding from endoscopy itself can occur, with a risk that varies according to procedure type and whether mucosal biopsies are performed. (See  <a class="medical medical_review" href="/z/d/html/2632.html" rel="external">"Management of antiplatelet agents in patients undergoing endoscopic procedures"</a> and  <a class="medical medical_review" href="/z/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis"</a> and  <a class="medical medical_review" href="/z/d/html/2553.html" rel="external">"Gastrointestinal endoscopy in patients with disorders of hemostasis", section on 'Estimating procedure-related bleeding risk'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients for whom it has been determined that antiplatelet therapy absolutely needs to be discontinued, there are no data on optimal timing for reintroduction of these agents or the appropriate doses that should be used. One small, prospective investigation (n = 156) examined reintroduction of low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in patients with cardiovascular disease and GI bleeding. All patients were treated with <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">pantoprazole</a> and then randomly assigned to either aspirin 80 mg daily or placebo after endoscopic therapy. Patients in the aspirin group had a nonsignificant increase in the incidence of recurrent GI bleeding (10.3 versus 5.4 percent; p = 0.25), but demonstrated a significantly lower all-cause mortality (1.3 versus 12.9 percent) [<a href="#rid30">30</a>]. In the placebo group, 5 of the 10 deaths were attributed to cardiovascular causes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Blood transfusion may be considered in patients with GI bleeding. However, the benefit of transfusion for periprocedural bleeding remains controversial, with some studies demonstrating the potential for harm. (See  <a class="medical medical_review" href="/z/d/html/1573.html" rel="external">"Periprocedural bleeding in patients undergoing percutaneous coronary intervention", section on 'Blood transfusion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Proton pump inhibitors (PPI) promote ulcer healing and prevent recurrence. Thus, for patients with GI bleeding, we recommend treatment with a PPI. The role of PPI in the management of GI bleeding related to ulcer disease is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/25.html" rel="external">"Peptic ulcer disease: Treatment and secondary prevention"</a> and  <a class="medical medical_review" href="/z/d/html/5.html" rel="external">"Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders"</a> and  <a class="medical medical_review" href="/z/d/html/2548.html" rel="external">"Approach to acute upper gastrointestinal bleeding in adults", section on 'Acid suppression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The potential interaction between PPI and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure", section on 'Interaction with other drugs'</a>.)</p><p></p><p class="headingAnchor" id="H5971641"><span class="h1">PREVENTION</span><span class="headingEndMark"> — </span>The primary prevention of gastrointestinal toxicity from nonsteroidal antiinflammatory drugs such as <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is presented in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1611.html" rel="external">"Stress ulcers in the intensive care unit: Diagnosis, management, and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"</a>.)</p><p class="headingAnchor" id="H108005888"><span class="h2">Proton pump inhibitors</span><span class="headingEndMark"> — </span>With regard to bleeding after percutaneous coronary intervention (PCI), observational studies have suggested that the use of proton pump inhibitors (PPIs) is associated with a significantly lower incidence of upper gastrointestinal (GI) bleeding within the first 30 days [<a href="#rid2">2</a>]. The COGENT trial tested the hypothesis that PPI therapy reduces the risk of GI bleeding in patients on long-term dual antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid31">31</a>]. In this trial, 3761 patients with an acute coronary syndrome or undergoing percutaneous coronary intervention were randomly assigned to <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">omeprazole</a> 20 mg or placebo daily. The following findings were noted with omeprazole therapy:</p><p class="bulletIndent1"><span class="glyph">●</span>The primary GI end point (a composite of overt or occult GI bleeding, symptomatic gastroduodenal ulcers or erosion, obstruction, or perforation) was significantly reduced (1.1 versus 2.9 percent; hazard ratio 0.34, 95% CI 0.18-0.63) at 180 days.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The rate of overt upper GI bleeding was significantly reduced (hazard ratio 0.13, 95% CI 0.03-0.56).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was no negative impact of <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">omeprazole</a> therapy on the primary composite cardiovascular end point in the COGENT trial (hazard ratio 0.99, 95% CI 0.68-1.44), despite some concern from observational studies that PPIs might have an adverse effect on cardiovascular outcomes in patients treated with <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid32">32</a>]. (See <a class="local">'Potential interaction with clopidogrel'</a> below.)</p><p></p><p class="bulletIndent1">However, because of the small number of cardiovascular events (109), the 95 percent confidence limits for this hazard ratio include a 32 percent decrease in cardiovascular events as well as a 44 percent increase in such events, leaving open the question of a clinically meaningful difference in cardiovascular events due to the use of a PPI. (See  <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure", section on 'Interaction with other drugs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a post-hoc analysis, the reduction in the rate of the primary GI end point with PPI therapy was seen in patients irrespective of whether they were receiving high-dose (150, 162, 300, or 325 mg) or low-dose (75 or 81 mg) <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid33">33</a>].</p><p></p><p>In terms of secondary prevention, PPIs reduce the risk of recurrent upper gastrointestinal bleeding. (See  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>.)</p><p>PPI should be given to the patient with a history of GI bleeding, need for triple antithrombotic therapy, or at high risk of bleeding. For patients in need of triple antithrombotic therapy, treatment should entail low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> (instead of <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>), <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> with target INR of 2.5, a PPI, and minimization of the duration of dual antiplatelet therapy.</p><p class="headingAnchor" id="H184413231"><span class="h3">Potential interaction with clopidogrel</span><span class="headingEndMark"> — </span>Despite early concerns about an interaction between <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> and PPIs, we think evidence does not support such an interaction. Meta-analyses have not clearly identified an increased risk of ischemic events with the use of PPIs in conjunction with clopidogrel. Some studies have cited increased rates of cardiovascular events attributable to PPIs, even without clopidogrel on board [<a href="#rid32">32,34</a>].</p><p>Reports in 2008 and 2009 raised concerns that some PPIs interfere with the ability of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> to inhibit platelet function and thereby increase the likelihood of coronary artery stent thrombosis (ST), myocardial infarction, or cardiovascular death. In addition, there may be genetic factors that influence the risk of drug interactions and the effectiveness of clopidogrel. More data are needed to clarify in which patients the risk of gastrointestinal bleeding outweighs the risk of a cardiovascular event associated with the possible drug interaction. For additional information on drug interactions, use the <a class="external" href="/drug-interactions">drug interaction program</a> provided by UpToDate. (See  <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure", section on 'Summary and recommendations'</a> and  <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure", section on 'Interaction with other drugs'</a>.)</p><p>The COGENT trial, discussed in the section above, gives reassurance of the safety of PPI therapy in combination with <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>.</p><p class="headingAnchor" id="H198538053"><span class="h3">Recommendations for use of proton pump inhibitors</span><span class="headingEndMark"> — </span>We recommend gastrointestinal prophylaxis for all patients undergoing PCI who are at high risk of an adverse gastrointestinal event consequent to therapy with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> (see <a class="local">'Incidence and risk factors'</a> above). In addition, we treat most patients taking <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a> or <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a> with PPIs. (See <a class="local">'Platelet P2Y12 receptor blockers'</a> above.)</p><p>Use of a PPI in patients on <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and a P2Y<sub>12</sub> receptor blocker not at high risk is also reasonable. PPI should be started as soon as possible after the initiation of dual antiplatelet therapy and continued indefinitely. For these lower-risk patients, factors such as complexity of the medical regimen, cost, or concern for the potential interaction between <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> and PPIs should be taken into account when deciding whether to prescribe PPIs indefinitely.</p><p>These recommendations are consistent with those made in the 2010 American College of Cardiology Foundation/American College of Gastroenterology/American Heart Association expert consensus document on the concomitant use of PPI and P2Y<sub>12</sub> receptor blockers [<a href="#rid35">35</a>]. The 2013 European Society of Cardiology expert position paper on the use of PPI in patients with cardiovascular disease and antithrombotic therapy makes similar recommendations and states that "PPIs with weaker inhibition of CYP219 are preferred in combination with <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> compared with those with stronger inhibition" [<a href="#rid36">36</a>].</p><p class="headingAnchor" id="H108005881"><span class="h2">Other drugs</span><span class="headingEndMark"> — </span>H2 receptor antagonists have <strong>not</strong> been shown to prevent ulcer bleeding in patients taking dual antiplatelet therapy, and are therefore of unproven benefit as an alternative to proton pump inhibitors. Because of the known ulcerogenic effects of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, the lowest dose for therapeutic efficacy should be used. (See  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use", section on 'Aspirin'</a> and  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Aspirin for all patients'</a> and  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Summary and recommendations'</a>.)</p><p class="headingAnchor" id="H878746646"><span class="h1">SCREENING FOR LONG-TERM GASTROINTESTINAL BLEEDING</span><span class="headingEndMark"> — </span>All patients treated with long-term oral antiplatelet therapy should have a complete blood count (CBC) either before or at the time of drug initiation. The finding of baseline anemia in a CBC should lead to testing the stool for occult blood. We do not perform period CBC to screen for GI bleeding unless there are symptoms or signs of bleeding.</p><p class="headingAnchor" id="H5971648"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence </strong>– Gastrointestinal (GI) bleeding occurs in 1.2 to 2.4 percent of percutaneous coronary intervention (PCI) patients. (See <a class="local">'Incidence and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes </strong>– GI bleeding is associated with increased early and late mortality, including a heightened risk of stent thrombosis. (See <a class="local">'Outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors </strong>– The risk factors for GI bleeding can be identified pre-procedurally. (See <a class="local">'Incidence and risk factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients being treated with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and a P2Y<sub>12</sub> receptor blocker (see <a class="local">'Prevention'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients felt to be at high risk of GI bleeding, we recommend GI prophylaxis with a proton pump inhibitor (PPI) (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients felt not to be at high risk of GI bleeding, we suggest GI prophylaxis with a PPI (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Such therapy should be started as soon as possible after the initiation of dual antiplatelet therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment </strong>– In the event of GI bleeding, appropriate management includes timely gastroenterology evaluation, endoscopy, and PPI administration. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1">Antithrombotic therapy should not be withheld unless the GI bleeding is life threatening. (See <a class="local">'Treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Abbas AE, Brodie B, Dixon S, et al. Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol 2005; 96:173.</a></li><li><a class="nounderline abstract_t">Chin MW, Yong G, Bulsara MK, et al. Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study. Am J Gastroenterol 2007; 102:2411.</a></li><li><a class="nounderline abstract_t">Nikolsky E, Stone GW, Kirtane AJ, et al. Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 54:1293.</a></li><li><a class="nounderline abstract_t">Yasuda H, Yamada M, Sawada S, et al. Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting. Intern Med 2009; 48:1725.</a></li><li><a class="nounderline abstract_t">Mehta SK, Frutkin AD, Lindsey JB, et al. Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry. Circ Cardiovasc Interv 2009; 2:222.</a></li><li><a class="nounderline abstract_t">Gaglia MA Jr, Torguson R, Gonzalez MA, et al. Correlates and consequences of gastrointestinal bleeding complicating percutaneous coronary intervention. Am J Cardiol 2010; 106:1069.</a></li><li><a class="nounderline abstract_t">Koskinas KC, Räber L, Zanchin T, et al. Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions. Circ Cardiovasc Interv 2015; 8.</a></li><li><a class="nounderline abstract_t">Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348:1413.</a></li><li><a class="nounderline abstract_t">Lai KC, Lam SK, Chu KM, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346:2033.</a></li><li><a class="nounderline abstract_t">Sørensen HT, Mellemkjaer L, Blot WJ, et al. Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin. Am J Gastroenterol 2000; 95:2218.</a></li><li><a class="nounderline abstract_t">Lanas A, Scheiman J. Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment. Curr Med Res Opin 2007; 23:163.</a></li><li><a class="nounderline abstract_t">Lanas A, Fuentes J, Benito R, et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16:779.</a></li><li><a class="nounderline abstract_t">Grove EL, Würtz M, Schwarz P, et al. Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. J Gen Intern Med 2013; 28:216.</a></li><li><a class="nounderline abstract_t">Fork FT, Lafolie P, Tóth E, Lindgärde F. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol 2000; 35:464.</a></li><li><a class="nounderline abstract_t">Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med 2005; 352:287.</a></li><li><a class="nounderline abstract_t">Ng FH, Wong SY, Chang CM, et al. High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease. Aliment Pharmacol Ther 2003; 18:443.</a></li><li><a class="nounderline abstract_t">Ma L, Elliott SN, Cirino G, et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci U S A 2001; 98:6470.</a></li><li><a class="nounderline abstract_t">Guo CG, Chen L, Chan EW, et al. Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y12 inhibitors compared with clopidogrel. Aliment Pharmacol Ther 2019; 49:7.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013; 368:1303.</a></li><li><a class="nounderline abstract_t">Alli O, Smith C, Hoffman M, et al. Incidence, predictors, and outcomes of gastrointestinal bleeding in patients on dual antiplatelet therapy with aspirin and clopidogrel. J Clin Gastroenterol 2011; 45:410.</a></li><li><a class="nounderline abstract_t">Berger PB, Bhatt DL, Fuster V, et al. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 2010; 121:2575.</a></li><li><a class="nounderline abstract_t">Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126.</a></li><li><a class="nounderline abstract_t">Ho PM, Peterson ED, Wang L, et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. JAMA 2008; 299:532.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52:1502.</a></li><li><a class="nounderline abstract_t">Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996; 93:215.</a></li><li><a class="nounderline abstract_t">Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98:2126.</a></li><li><a class="nounderline abstract_t">Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084.</a></li><li><a class="nounderline abstract_t">Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665.</a></li><li><a class="nounderline abstract_t">Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98:1597.</a></li><li><a class="nounderline abstract_t">Sung JJ, Lau JY, Ching JY, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010; 152:1.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010; 363:1909.</a></li><li><a class="nounderline abstract_t">Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study. Ann Intern Med 2010; 153:378.</a></li><li><a class="nounderline abstract_t">Vaduganathan M, Bhatt DL, Cryer BL, et al. Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy. J Am Coll Cardiol 2016; 67:1661.</a></li><li><a class="nounderline abstract_t">Kwok CS, Jeevanantham V, Dawn B, Loke YK. No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis. Int J Cardiol 2013; 167:965.</a></li><li><a class="nounderline abstract_t">Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. Circulation 2010; 122:2619.</a></li><li><a class="nounderline abstract_t">Agewall S, Cattaneo M, Collet JP, et al. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J 2013; 34:1708.</a></li></ol></div><div id="topicVersionRevision">Topic 13605 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16018836" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Incidence and prognostic impact of gastrointestinal bleeding after percutaneous coronary intervention for acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17850413" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Predictive and protective factors associated with upper gastrointestinal bleeding after percutaneous coronary intervention: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19778672" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19797827" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Upper gastrointestinal bleeding in patients receiving dual antiplatelet therapy after coronary stenting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20031719" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20920640" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Correlates and consequences of gastrointestinal bleeding complicating percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25910501" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8937281" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12087138" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11007221" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17257477" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11929396" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22948933" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Gastrointestinal events with clopidogrel: a nationwide population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10868447" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15659730" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Reducing the risks of gastrointestinal bleeding with antiplatelet therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12940930" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : High incidence of clopidogrel-associated gastrointestinal bleeding in patients with previous peptic ulcer disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11353854" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30506985" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Systematic review with meta-analysis: the risk of gastrointestinal bleeding in patients taking third-generation P2Y12 inhibitors compared with clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23473369" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of platelet inhibition with cangrelor during PCI on ischemic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20975574" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Incidence, predictors, and outcomes of gastrointestinal bleeding in patients on dual antiplatelet therapy with aspirin and clopidogrel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20516378" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15870416" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18252883" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19017521" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8548891" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9815866" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8598866" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9834303" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778323" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19949136" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20925534" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Clopidogrel with or without omeprazole in coronary artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20855802" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27012778" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Proton-Pump Inhibitors Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22464478" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21060077" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : ACCF/ACG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23425521" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
